赖氨酰氧化酶样蛋白2在肺腺癌患者中的预后价值  

Prognostic Value of Lysyl Oxidase-Like 2 in Patients with Lung Adenocarcinoma

作　　者：展平[1] 谢海燕[1] 

机构地区：[1]南京市胸科医院,江苏南京210029

出　　处：《肿瘤学杂志》2017年第11期973-977,共5页Journal of Chinese Oncology

摘　　要：[目的]探讨LOXL2在肺腺癌中的表达情况及与临床病理特征预后意义。[方法]采用免疫组化染色(Immunohistochemical staining,IHC)的方法检测60对配对的肺腺癌及癌旁组织中LOXL2蛋白的表达水平,并根据免疫组化染色评分判断LOXL2蛋白的表达强度,分析LOXL2蛋白表达与肺腺癌临床病理特征以及预后的相关性。[结果]LOXL2蛋白在癌组织中显著性高表达。LOXL2蛋白在肺腺癌组织中主要定位于细胞核。细胞核LOXL2高表达与肺腺癌的淋巴结转移(P=0.025)、TNM分期(P=0.031)相关,并是肺腺癌差预后的独立预测因子(P=0.028)。[结论]细胞核LOXL2蛋白的高表达与肺腺癌患者的差预后相关,LOXL2可以作为肺腺癌患者的一种新的预后生物指标和潜在的治疗靶点。[Purpose] To assess the prognostic value of lysyl oxidase-like 2（LOXL2） in patients with lung adenocarcinoma （AD）. [Methods] LOXL2 protein levels were detected in 60 samples of lung AD and pericancerous lung tissues with immunohistochemical and its clinicopathologic and prognostic significance was analyzed. [Results] LOXL2 protein levels were higher in lung AD tissues than those in paired adjacent normal tissues. High LOXL2 levels were associated with increased lymph node metastasis and advanced p-TNM stage,LOXL2 levels were an independent prognostic factor in lung AD. [Conclusion] LOXL2 protein levels are associated with poor prognosis in lung AD patients. LOXL2 might serve as a prognostic biomarker and potential therapeutic target in lung AD patients.

关 键 词：赖氨酰氧化酶样蛋白2 LOXL2 肺腺癌 预后 转移 

分 类 号：R734.2[医药卫生—肿瘤]